摘要
Abstract
Objective To investigate the clinical efficacy of Oxaliplatin containing chemotherapy regimen in patients with Sorafenib resistant advanced primary liver cancer. Method 64 patients with Sorafenib resistant advanced primary liver cancer who were treated in our hospital from May 2014 to May 2016 were selected, these patients were randomly divided into study group (n = 32) and control group (n = 32), the efficacy, alpha fetoprotein (AFP) level, survival time and adverse reaction were compared between the two groups. Result The total effective rate of study group was significantly higher than that of control group (P < 0.05), the AFP level was significantly lower than that of control group after treatment (P < 0.05), the median progression disease and median survival time were significantly longer than that of control group (P < 0.05), the survival rate was significantly higher than that of control group (P < 0.05), continue the treatment rate and mortality were significantly lower than that of control group (P < 0.05), but the differences of leukopenia, thrombocytopenia, liver dysfunction, nausea and vomiting, diarrhea, hand-foot syndrome, peripheral nerve toxicity and other side effects incidence rates between the two groups were not significant (P>0.05). Conclusion Oxaliplatin containing chemotherapy can effectively reduce the serum AFP level and prolong survival of patients with Sorafenib resistant advanced primary liver cancer.关键词
奥沙利铂/索拉非尼耐药/原发性肝癌/不良反应/甲胎蛋白/生存期Key words
Oxaliplatin/Sorafenib resistant/Primary liver cancer/Toxicity/Alpha-fetoprotein/Survival time
